Condition
Ovarian Tumors
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Not Yet Recruiting1
Suspended1
Completed1
Unknown1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07480785Not ApplicableRecruiting
TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients
NCT06703112Not ApplicableNot Yet RecruitingPrimary
Establishment and Clinical Application of AI-based Multimodal Diagnosis System for Ovarian Tumors
NCT04711161Phase 1SuspendedPrimary
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
NCT01698632Unknown
International Ovarian Tumour Analysis (IOTA) Phase 5
NCT01304043CompletedPrimary
French Observatory of Rare Malignant Tumors of the Ovary
Showing all 5 trials